Skip to main content
Log in

Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Azithromycin, a recently introduced antibiotic, offers the potential advantages of short-course administration and lower toxicity compared to other macrolides. Approved for the treatment of mild pneumonia, this drug was investigated in a study of patients hospitalized for community-acquired pneumonia. In an open-labelled randomized study, oral azithromycin was compared with intravenous benzylpenicillin in patients suspected to have pneumonococcal pneumonia. Azithromycin was also compared with erythromycin, both administered orally, in all other patients. Three hundred thirty-four patients with community-acquired pneumonia were hospitalized, 108 of whom were randomized; 104 could be evaluated. A need for intravenous therapy was the most common reason for exclusion. In the pneumococcal group, 35 patients received azithromycin and 29 benzylpenicillin. The clinical and radiological success rate achieved with azithromycin (83 %) was considerably higher than that achieved with benzylpenicillin (66 %), though the difference was not significant. In the non-pneumococcal group, 19 patients received azithromycin and 21 erythromycin; no differences in the success rate were found (79 % and 76 %, respectively). Eight patients on azithromycin had a blood culture positive forStreptococcus pneumoniae; in three of these patients therapy was changed. None of the five patients with pneumococcal bacteraemia who received benzylpenicillin required a change in therapy. It is concluded that oral azithromycin, administered as short-course therapy, is an appropriate antibiotic for treating patients with community-acquired pneumonia. However, it is not yet certain that azithromycin is a good choice for patients with pneumococcal bacteraemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Garibaldi RA: Epidemiology of community-acquired respiratory tract infections in adults. American Journal of Medicine 1985, 78, Supplement 6B: 32–37.

    CAS  PubMed  Google Scholar 

  2. Macfarlane JT: Community-acquired pneumonia. British Journal of Diseases of Chest 1987, 81: 116–127.

    CAS  Google Scholar 

  3. Macfarlane JT: Recent advances in respiratory medicine. Churchill Livingstone, Edinburgh, 1991, p. 109–124.

    Google Scholar 

  4. Fang G, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston TJ, Wang SP, Kohler R, Muder RR, Yee YC, Rihs JD, Vickers RM: New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 1990, 69: 307–316.

    CAS  PubMed  Google Scholar 

  5. Pennington JE: Respiratory infections: diagnosis and management. Raven Press, New York, 1988, p. 159–171.

    Google Scholar 

  6. Musher DM: Infections caused byStreptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clinical Infectious Diseases 1992, 14: 801–809.

    CAS  PubMed  Google Scholar 

  7. Research Committee of the British Thoracic Society: Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. British Journal of Hospital Medicine 1993, 49: 346–350.

    Google Scholar 

  8. Ball P: The future role and importance of macrolides. Journal of Hospital Infection 1991, 19, Supplement A: 47–59.

    PubMed  Google Scholar 

  9. Bahal N, Nahata MC: The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Annals of Pharmacotherapy 1992, 26: 46–55.

    CAS  PubMed  Google Scholar 

  10. Peters DH, Friedel HA, McTavish D: Focus on azithromycin. Drugs 1992, 44: 750–799.

    CAS  PubMed  Google Scholar 

  11. Neu HC: Clinical microbiology of azithromycin. American Journal of Medicine 1991, 91, Supplement 3A: 12–18.

    Google Scholar 

  12. Schentag JJ, Ballow CH: Tissue-directed pharmacokinetics. American Journal of Medicine 1991, 91, Supplement 3A: 5–11.

    Google Scholar 

  13. Coonrod DJ: Pneumococcal pneumonia. Seminars in Respiratory Infections 1989, 4: 4–11.

    CAS  PubMed  Google Scholar 

  14. Kuikka A, Syrjanen J, Renkonen O, Valtonen VV: Pneumococcal bacteraemia during a recent decade. Scandinavian Journal of Infectious Diseases 1992, 24: 157–168.

    CAS  Google Scholar 

  15. Örtqvist A, Kalin M, Julander I, Mufson MA: Deaths in bacteremic pneumococcal pneumonia: a comparison of two populations in Huntington, West Virginia, and Stockholm, Sweden. Chest 1993, 103: 710–716.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bohte, R., van't Wout, J.W., Lobatto, S. et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 14, 182–187 (1995). https://doi.org/10.1007/BF02310353

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02310353

Keywords

Navigation